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Abstract 
Early stage detection and cancer treatment demand the identification of reliable biomarkers. 
Over the past decades, efforts have been devoted to assess the variation of glycosylation level 
as well as the glycan structures of proteins in blood or serum, associated with the 
development and/or progression of several cancers, including liver. Herein, an LC-MS/MS-
based analysis was conducted to define the glycosylation patterns of haptoglobin 
glycoprotein derived from sera collected from cirrhotic and hepatocellular carcinoma (HCC) 
patients. The haptoglobin samples were extracted from serum using an antibody-immobilized 
column prior to the release of N-glycans. A comparison of non-isomeric and isomeric 
permethylated glycan forms was achieved using C18 and porous graphitic carbon (PGC) 
columns, respectively. In the case of C18-LC-MS/MS analysis, 25 glycan structures were 
identified of which 10 sialylated structures were found to be statistically significant between 
the two cohorts. Also, 8 out of 34 glycan structures identified by PGC-LC-MS/MS were 
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found to be statistically significant, suggesting that isomeric distributions of a particular 
glycan composition were different in abundances between the two cohorts. The glycan 
isoform patterns distinguished early stage HCC from cirrhotic patients. Both retention times 
and tandem mass spectra were utilized to determine the specific isomeric glycan structures. 
All of the glycan isomers, which were statistically significant, were either branch fucosylated 
or composed of α-2,6 linked sialic acid moieties. The result of this study demonstrates the 
potential importance of isomeric separation for defining disease prompted aberrant glycan 
changes. The levels of several glycan isomers effectively distinguished early stage HCC from 
cirrhosis.  
 
1. Introduction 
Hepatocellular carcinoma (HCC) is a common cancer type with a mortality rate that 
ranks third among cancer-related deaths in the world [1-3]. It is well known that a large 
percentage of HCC cases develop from liver cirrhosis, where physicians monitor these 
patients in the clinic for potential cancer development [4]. Due to its poor survival rate at 
advanced stages[5], the early stage detection of the transition from cirrhosis to HCC is 
necessary to receive effective clinical therapy. To date, several serum protein biomarkers 
have been reported and used clinically for HCC detection [6-8]. Serum alpha-fetoprotein 
(AFP), as an example, has been used as a general clinical biomarker for detection of HCC. 
However, AFP level can be affected by several factors, including gender, race, and the 
presence of onsets of other diseases such as chronic hepatitis [9]. Among patients with 
chronic hepatitis C, AFP concentration exhibits false positive in HCC diagnosis [10]. 
Although AFP can generally achieve an area under the curve (AUC) of > 0.8 for detection of 
HCC versus cirrhosis, effective markers for early detection of HCC are still lacking.  
Glycosylation is considered as an important post-translational modification of 
proteins, which has a great impact on biological processes, such as cell-cell interaction, 
recognition, immune response and adhesion [11, 12]. Recently, the fucosylation level 
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associated with different glycoproteins has been implicated in several cancer-related diseases, 
including pancreatic cancer [13], gastric cancer [14], and breast cancer [15]. Lectin-affinity 
electrophoresis using Lens culinaris agglutinin-A (specific for core-fucosylated glycan 
structures) was employed to detect HCC at early stages [16-18]. The levels of AFP in the 
blood serum collected from HCC patients interacted strongly with Lens culinaris agglutinin-
A relative to that of patients with other liver diseases [16-18]. However, the accuracy of this 
method was determined to be limited [19].  
Recent studies have demonstrated that either glycosylation patterns of human serum 
or fucosylation levels of extracted haptoglobin were different between cirrhosis and HCC 
[20, 21]. Although several glycans were suggested as potential biomarkers, isomeric 
structures of these glycans were not determined. Previously, sialic acid linkages have been 
shown to be relevant to several types of carcinoma cells [22, 23]. Mondal et al. used 
Sambucus nigra agglutinin and Maackia amurensis agglutinin lectin materials to identify the 
levels of -2,6 and -2,3 linkage of sialic acids associated with AFP [24]. Elevated levels of 
-2,6 linked sialic acid expression in AFP was observed in patients with hepatitis B cirrhosis 
while elevated levels of -2,3 linked sialic acids in AFP was observed in patients with 
hepatitis C cirrhosis, respectively [24]. Thus, it is rational to assume that the profiling of 
isomeric glycan structure of haptoglobin might effectively discriminate between cirrhosis and 
HCC.  
LC-MS/MS is currently considered a great tool for biomolecule identification, 
enabling simultaneous glycan isomeric separation and structural assignment. Various 
separation techniques have been developed to resolve glycan isomers at both the glycan and 
glycopeptide levels [25-29]. Hydrophilic liquid interaction chromatography (HILIC) coupled 
with reducing end labeling or derivatization is an excellent approach to separate glycans or 
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glycopeptides [30]. However, in positive mode, the ionization efficiency of native glycans 
especially sialylated species hinders the direct analysis of such species [31, 32]. Porous 
graphitic carbon (PGC) chromatography is another separation technique that is commonly 
used for the separation of glycans. PGC columns have unique ionic interaction with the 
analytes, prompting efficient separation. Studies that are detailing native and reducing end 
labeled glycans separation on PGC columns have been recently reviewed [33, 34]. However, 
the weak ionization of both native and some reducing-end labeled glycans does not permit 
sensitive analyses. 
As a quick and  efficient derivatization method, solid-phase permethylation has been 
used to dramatically increase the ionization efficiency of glycans, including sialylated 
structures [35, 36]. Recently, we have reported for the first time the isomeric separation of 
permethylated glycans at high sensitivity and efficiency, using PGC columns at high 
temperatures [37]. The LC resolution enhancement achieved in this study by elevating 
column temperature permitted the acquisition of tandem mass spectrum of each isomeric 
structure. With the combination of retention time and MS/MS, a series of isomeric forms of 
standard glycans were unequivocally characterized [37]. Here, we are applying the same 
method to assess changes in isomeric glycans resulting from the development of HCC. We 
are also comparing such data to what other data acquired to non-isomeric C18 analysis results. 
2. Materials and Methods 
2.1 Chemicals and Reagents 
PNGase F was obtained from New England Biolabs (Ipswich, MA). The mouse anti-
human haptoglobin antibody was purchased from Abcam (Cambridge, MA). Borane-
ammonia complex, sodium hydroxide beads, and iodomethane were acquired from Sigma-
Aldrich (St. Louis, MO). Dimethyl sulfoxide (DMSO) was bought from Mallinckrodt 
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Chemicals (Phillipsburg, NJ). HPLC grade methanol and acetonitrile were purchased from 
Fisher Scientific (Fair Lawn, NJ). HPLC water was obtained from Avantor (Central Valley, 
PA). Spin columns were purchased from Harvard Apparatus (Holliston, MA). 
Serum samples were provided by the University Hospital, Ann Arbor, Michigan 
according to IRB approval (10 cases of hepatocellular carcinoma (HCC) and 10 cases of liver 
cirrhosis.) The clinical information associated with the samples used in this study are 
summarized in Table 1 and Table S1.  
2.2 Purification of Haptoglobin from Serum 
Haptoglobin was purified from a 20-μL aliquot of serum for each patient by using an 
HPLC-based antibody-immobilized column developed in-house as previously reported [38]. 
Briefly, the mouse anti-human haptoglobin antibody was covalently immobilized on the 
UltraLink hydrazide resin (Thermo Scientific, Rockford, IL) and then packed into a PEEK 
column (4.6 mm × 50 mm). The immunoaffinity purification of haptoglobin was performed 
on a Beckman Coulter ProteomeLab PPS system (Fullerton, CA) based on the HPLC 
platform developed previously [38]. The bound haptoglobin fraction was eluted with 
stripping buffer (0.1 M Glycine, pH 2.5) and then immediately neutralized with 0.1 M Tris-
HCl (pH 8.0). Subsequently, the enriched haptoglobin was desalted using a YM-3 centrifugal 
filter device (Millipore, Billerica, MA) by buffer exchange with water for three times and 
then dried down in a SpeedVac concentrator (Thermo). Before glycan release, the purity of 
the eluted haptoglobin was confirmed by 1D SDS-PAGE followed by silver staining using 
ProteoSilver™ Plus Silver Stain Kit (Sigma). 
2.3 N-Glycan Release from Serum Haptoglobin 
The N-glycans of haptoglobin were released and extracted according to the procedure 
described previously [39]. The purified haptoglobin was dissolved in 9 μL of deionized water, 
followed by adding a 1-μL aliquot of denaturing solution (0.2% SDS, 100 mM 2-
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mercaptoethanol), and incubated at 60 ºC for 30 min. After cooling down, 4.3 L of 
ammonium bicarbonate (50 mM) solution was added to obtain a final concentration of 15 
mM. A 0.4-μL aliquot of PNGase F (two units). was added and incubated with the sample at 
37 ºC for 16 h, followed by quenching the enzymatic reaction at 95 ºC for 10 min. The 
mixture of the released N-glycans and the protein were dried in a SpeedVac concentrator. 
Finally, N-glycans were extracted using porous graphitized carbon tips (Sigma) and then 
dried prior glycan permethylation and MS analysis.  
2.4 Permethylation of released N-glycans 
The released haptoglobin glycans from both cirrhosis and HCC samples were reduced 
and permethylated following the conventional protocol as previously described [36, 40, 41]. 
Briefly, an aqueous reduction borane-ammonia complex solution was prepared (composed of 
10 μg/μL prepared in HPLC water) . A 10-μL aliquot of the reduction borane-ammonia 
complex solution was added to each free glycan sample and incubated at 60 ºC in a water 
bath for 1 hour. The reduced glycans were then washed with methanol and dried in a 
SpeedVac concentrator. This step was repeated to remove borate salt.  The step was repeated 
several times until no white pellet was observed after drying. 
Sodium hydroxide beads were soaked in DMSO and loaded into a spin column for 
solid-phase permethylation. The beads were drained by centrifuging in the spin column and 
washed one more time with DMSO. At the same time, the reduced glycans were resuspended 
in 30-μL DMSO, 20-μL iodomethane, and 1.2-μL HPLC water aliquots before applying to 
the spin columns. An additional 20-μL aliquot of iodomethane was added to the spin column 
after incubation for 25 min and incubated for another 15 min. The spin column was then 
centrifuged and washed with a 30-μL aliquot of acetonitrile (ACN). Finally, the collected 
solutions were dried overnight in SpeedVac concentrator and then resuspended in 20% ACN, 
0.1 % formic acid (FA) buffer prior to LC-MS/MS analysis. 
  
 
This article is protected by copyright. All rights reserved. 
7 
 
2.5 LC-MS/MS conditions 
Although it is important to analyze the sample in random order, however, our 
previous results have demonstrated that the reproducibility and stability of both C18 and 
PGC-LC-MS/MS facilitated comparable results with and without randomization. Therefore, 
10 cirrhosis samples, in both methods, were analyzed prior to the 10 HCC samples. 
2.5.1. C18-LC-MS/MS conditions. After permethylation, the separation was 
conducted on an Acclaim PepMap C18 column (75 μm× 15 cm, 2 μm, 100 Å; Thermo 
Scientific, Pittsburgh, PA) using ultimate 3000 nanoUHPLC system (Dionex, Sunnyvale, 
CA). The previously employed LC at 55°C conditions was applied here [20]. Briefly, mobile 
phase A contains 98% HPLC water, 2% ACN, 0.1% FA, while mobile phase B is 100% ACN 
with 0.1% FA. The gradient started at 20% mobile phase B for the beginning 10 min and 
increased to 38% at 11 min. In the next 32 minutes, the organic phase gradually developed to 
60%. After that, it ramped to 90% within 3 min and was maintained for 4 min. Finally, the 
percentage of mobile phase B dropped to 20% in 1 min and kept at that percentage for 9 min 
to pre-equilibrate the system. The nanoUHPLC system was interfaced to an LTQ Orbitrap 
Velos (Thermo Scientific, San Jose, CA) for MS analysis. The full MS range was set to 700-
2000 m/z with a resolution of 15,000, followed by CID and HCD DDA (data-dependent 
analysis) MS/MS scans on the top 4 most intense ions. The activation energy of CID was set 
to 30% normalized energy with a 15 ms activation time while a 45% normalized energy was 
used for HCD with 0.1 ms of activation. In both fragmentation methods, activation Q value 
was set to 0.250.  
2.5.2. PGC-LC-MS/MS conditions. The PGC-LC-MS/MS was performed using a 
high-temperature separation technique reported by our group previously [37]. The separation 
was performed on the same UHPLC platform with a HyperCarb PGC column (75 μM × 100 
mm, 5 μM particle size; Thermo Scientific, Pittsburgh, PA). The temperature was set to 75°C 
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to achieve the optimized separation. The content of mobile phase A and B were the same as 
the C18 separation mentioned above. A flux of 350 nL/min instead of 650 nL/min in the 
previous work was conducted on the column to obtain an improved resolution and higher 
intensity. The elution began with 20% of mobile phase B for 10 min and ramped to 35% at 11 
min. The content of mobile phase B was increased to 60% in the next 9 minutes linearly. 
Then the increasing rate slightly slowed down and reached 90% at 46 min. High organic 
phase was maintained for 11 minutes. Finally, the gradient decreased to 20% in 1 min and 
column equilibrated for 2 minutes at 20% B. Tandem MS was set to scan the top 6 most 
intense ions, while the other settings remained the same as the C18-LC-MS/MS method.  
3. Results and discussion  
To simplify the annotation of glycan structures, a 4-digit nomenclature was employed 
here.  Each digit represented the number of monosaccharides associated with an N-glycan 
structure in the following order: HexNAc–hexose–fucose–sialic acid (see Scheme 1). The 
quantification of N-glycan structures was based on the sum of peak areas of the extracted ion 
chromatogram (EIC) for each glycan using theoretical m/z values representing proton 
molecular ion as well as ammonium and sodium molecular ion adducts with a mass tolerance 
of 10 ppm. Each peak was assigned and integrated manually. All peak areas were normalized 
by total peak areas.  
3.1 C18-LC-MS/MS analysis 
Initially, C18-LC-MS/MS analysis of permethylated glycans was used to identify the 
glycan structures between the different cohorts. Totally, 25 glycan structures were identified 
and quantified (Table S2). Unsupervised principal component analysis (PCA) was performed 
using Markerview™ (AB Sciex, Framingham, MA) in which all data points were analyzed 
without designation to avoid overfitting of data. The group properties of the 20 samples were 
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analyzed using the relative abundances of each glycan structure calculated as described above. 
The PCA plot is shown in Figure 1 in which the glycosylation pattern of the cirrhosis and 
HCC samples can be mostly discriminated, although two samples did not correctly cluster. 
Loading plot of unsupervised PCA is depicted in Figure S1. Fucosylated structures seem to 
be primarily responsible for the discrimination in the PCA plot. Two-tailed student t-test was 
performed on the quantitative data similar to what have been used in biomarker studies 
performed by other groups [25, 42, 43]. Among the 25 glycan structures, 10 demonstrated 
significant discrimination with a p-value lower than 0.05. Figure 2 depicts the base peak 
intensity chromatograms for samples representing both cirrhosis and HCC. In Figure S2, the 
EIC of the significant glycans in cirrhosis and HCC samples were compared, demonstrating 
an excellent reproducibility regarding retention time and resolution. The glycans were well 
resolved by the C18 reversed-phase chromatography, even though some structures showed 
relatively low abundances. The retention time largely depended on the size of glycan 
structures and the number of sialic acids. The retention time order of elution is used to 
eliminate false positives, resulting from m/z overlap [20].  
The abundance of glycans in cirrhosis and HCC samples was compared. Box plots 
illustrating the abundance of the statistically significant glycan structures are shown in 
Figure 3. All the statistically significant glycan structures were sialylated. Except [4-5-0-1], 
9 sialylated glycans were upregulated in HCC relative to cirrhosis. Although the two 
tetraantennary difucosylated structures revealed a significant difference and were previously 
demonstrated as a potential biomarker to distinguish cirrhosis and HCC [38, 39, 44, 45], the 
most significant difference lay in [6-7-1-3] and [6-7-1-4] in our case. ROC curves of the 6 
most significant glycans were generated and depicted in Figure S3. Although the sample 
sizes were not large enough, the area under curves for all six structures are higher than 0.8, a 
value defined to be indicative of potential biomarkers.  
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Unlike previous studies, the neuraminidase digestion was not necessary for the current 
study due to the enhancement in ionization efficiency of sialylated species by permethylation. 
Therefore, the glycans differing in the numbers of sialic acids can be revealed by 
permethylation. It is also worth mentioning that instead of commonly-seen core fucosylation, 
the glycans derived from these samples were highly branch-fucosylated. This discovery 
agrees with a reported glycoform profiling results of serum haptoglobin derived from prostate 
cancer patients and control subjects.[46] In Figure 4, the heat map generated from the 
relative abundances of each of the glycans also illustrated that tetraantennary sialic acids are 
more abundant in HCC haptoglobin, while monosialylated biantennary glycan [4-5-0-1] was 
downregulated in cirrhosis relative to HCC. Also, from the cluster tree labeled in the heat 
map, fucosylated tetraantennary species showed similarity with each other, and non-
fucosylated classified in a different category.  
Our C18-LC-MS/MS analysis of permethylated glycans permitted the identification 
of more glycans than the previous studies of haptoglobin glycosylation patterns in various 
types of cancer-related diseases. Previously, only 8 glycan structures were identified and 
quantified since N-neuraminidase was employed to remove sialic acids prior to analysis [39]. 
Fujimura et al. study, identified 16 permethylated haptoglobin glycan structures derived from 
blood sera of prostate cancer patients [46].  All 16 glycan structures were identified in our 
study except for one In another study, 10 glycans derived from haptoglobin isolated from 
blood sera collected from pancreatic cancer patients were identified by pyridylamino (PA) 
reducing end labeling and LC-MS analysis [47]. Accordingly, our C18-LC-MS/MS analysis 
of permethylated glycans provided the highest sensitivity as suggested by the number of 
glycans detected.  This great sensitivity is expected since permethylation enhances MS 
ionization by at least 2-orders of magnitudes relative to native glycans [48, 49].   
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Since the quantitation results were achieved using C18-LC-MS/MS, the detailed 
information about glycan isomers including sialic acid linkage isomers and fucosylation 
isomers could not be well defined. Therefore, we employed our newly developed PGC-LC-
MS/MS analysis of permethylated glycans [37] to provide insights about the roles of glycan 
isomers in the development of HCC.  
3.2 PGC-LC-MS/MS analysis 
After a logarithmic transformation of the normalized abundance values, Figure 5 
depicts unsupervised PCA plot of the glycans resolved on PGC columns. The numerical data 
for quantitation are summarized in Table S3. Loading plot is depicted in Figure S4. 
Fucosylated structures are still responsible for the discrimination shown in the PCA plot. The 
result demonstrated the difference between glycosylation patterns of cirrhosis and HCC 
haptoglobin to be noticeably similar to what was observed in the case of C18 separation 
(compare Figures 1 and 5).  
As shown in Figure 6, a boxplot comparison was utilized to describe the 
discrimination in the normalized abundance of the statistically significant glycan structures 
determined by t-test. The [4-5-0-1] glycan structure in the case of PGC-LC-MS/MS analysis 
was also the most abundant glycan with statistical significance.  This structure exhibited a 
downregulation between cirrhosis and HCC. ROC curves of the 6 most significant glycans 
were generated and depicted in Figure S5. AUCs were shown in the inset of Figure S5, 
suggesting a good ability for these structures distinguish cirrhosis and HCC samples.   
The assignments of the isomers were based on three criteria: CID MS/MS, retention 
time and elution order. For the fucosylated glycans, since the possibility of forming isomers 
resulted from the fucose attachment to core or branch GlcNAc, the diagnostic fragment ions 
at m/z 468.4 999.7 and 638.5, etc. can be employed to distinguish between the different 
structure isomers [37]. Also, sialic acids with a α-2,6 linkage always eluted 3-4 minutes later 
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than its counterpart with α-2,3 linkage, regardless of the branch to which it is attached as 
shown previously [50]. Based on this fact, [4-5-0-1] can be specified to α-2,6 linkage 
according to the retention time when compared to the standard glycans from bovine fetuin 
[37]. EIC of [4-5-0-2] and [5-6-0-1] glycan isomers are depicted in Figure S6 and SI 7, 
respectively.  
Figure 7 depicts the EIC of protonated [4-5-1-1] at m/z 867.1213, in which four peaks 
were detected in both cirrhosis (Figure 7a) and HCC (Figure 7b). The most intense peak was 
significantly more abundant in HCC haptoglobin compared to liver cirrhosis. The assignment 
of fucosylation positions was based on its MS/MS spectrum depicted in Figure 7c. As we 
noticed, the most commonly used characteristic peak for core-fucosylated glycans at m/z 
468.3 was not present in this spectrum. Instead, a fragment at m/z 1153.9 and m/z 966.4 
provided solid evidence of branch-fucosylation, since, for permethylated glycans, fucose 
migration was not possible. Thus, the only reasonable explanation was the existence of a 
branch-fucosylated structure. Moreover, the fact that sialic acid and fucose were attached to 
different arms was revealed. According to the presence of fragments at m/z 638.5 and 825.6, 
the possibility of sialyl-Lewis x (SLex) was ruled out. Although the arm attachment (i.e. 
whether fucose was attached to the α3 or α6 arms) remained unknown, the fucosylation and 
sialylation sites were confirmed.  
Since the first peak at 27.2 min exhibits similar MS/MS pattern (Figure S8) as the 
second peak, we considered them as both branch-fucosylated glycans, even though the sialic 
acid is attached to different branches. However, the third peak (Figure S9) and the fourth 
peak (Figure S10) both had distinct MS/MS spectra from the first two peaks, where the 
diagnostic peaks for core-fucosylation at m/z 468.3 were presented in both cases. Thus, the 
first two peaks were considered as branch-fucosylated, and the latter two were the core-
fucosylated peaks. The sialic acid linkages were annotated based on the retention time where 
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the rule of the elution order was applied. Therefore, the first eluting peak was assigned as α-
2,3 linkage and the second one was recognized as α-2,6 linked.  
Another issue worth mentioning is that two of the PGC-significant structures, [4-5-1-1] 
and [5-6-1-3], were not detected by t-test upon C18 quantitation. It is possible that these two 
specific isomers were masked by the other non-significant ones with the same m/z. Therefore, 
an isomeric separation on PGC could provide additional potential biomarkers for early stage 
liver cancer diagnostic. Even though the p-value is relatively high for these glycans, the 
advantage in abundance could make it useful as a potential biomarker. Compared to our C18 
t-test result, tetra-sialylated structures and other large sized glycans were missing in the PGC-
LC-MS/MS analysis. On the one hand, it is possible that some of the structures or isomers 
were not eluted due to the strong retention feature of the PGC column material. On the 
contrary, after the isomers were separated, the intensity would decrease evidently to the point 
below the limit of quantitation (LOQ) or even limit of detection (LOD). This applies 
especially to the complex structures since the theoretical numbers of isomeric structures 
increase exponentially with the size of the structure. Nevertheless, according to the box-plot 
result, the most significant glycan was the isomer of [5-6-2-3] that eluted first on the column. 
As noticed, the highly sialylated structures were less significant in the case of PGC separation. 
Although carry-over in PGC because of the strong interaction between the column and the 
analytes has been previously reported [51], these non-eluting isomers could be more 
significance in this case. In Figure 8, the cluster properties were described in a heat map. 
Except for α-2,6 linked [4-5-1-1], all other structures can be clustered into an upregulated 
group, which suggests that the transformation of cirrhosis to HCC could promote an 
increased expression of fucosylated and sialylated structures.  
Although efforts have been devoted to assigning the fucosylation sites of glycoforms 
associated with HCC, separation of the glycan isomers, as well as the sialic acid linkages, 
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largely remained unclear. Previously, the glycan isomers caused by the difference in 
fucosylation sites were noticed and illustrated by MS/MS and MS
3
; however, no isomeric 
assignment was reported [52]. IMS/MS were also utilized for glycan profiling in serum from 
HCC patients. Although the isomeric structures of [4-5-0-1] were resolved and compared, the 
assignment was not achieved [5353]. To our knowledge, this is the first work that 
quantitatively compares the glycosylation pattern between cirrhosis and HCC at the isomeric 
level in which glycan isomers are identified.  
4. Conclusion  
In this study, N-glycans released from haptoglobin purified from the serum of 
cirrhotic and HCC patients were analyzed by C18 and PGC liquid chromatography. The 
glycan structures associated with cirrhosis and HCC exhibited a discernible pattern. In C18 
separation, 10 glycan structures were found to be significant; while on the PGC column, 8 
glycan isomers were considered quantitatively unique. Determination of sialic acid and 
fucose linkages was facilitated by PGC-LC-MS/MS analysis. This work shows that glycan 
isomers would make a difference in quantitative pattern characteristics in the biomarker 
discovery process, where the technique can even be applied to early stage cancer detection. 
Therefore, future efforts will be devoted to isomeric glycans as biomarkers and their 
biological synthesis pathway that potentially influences the glycosylation pattern of 
haptoglobin in blood serum.   
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Table 1. Patient Clinical Information. 
Disease diagnosis HCC Cirrhosis 
Number 10 10 
Etiology% (HBV/HCV/ALC)
a
 10/60/30 20/50/30 
Gender % (M/F) 70/30 60/40 
Age (mean ± SD) 58.9 ± 11 60.0 ± 7 
AFP level
b
 (median), ng/mL 9.35 3.80 
MELD
c
 score 9.8 ± 5.6 9.3 ± 1.9 
TNM stage % (I/II/III/IV) 0/70/10/20 NA 
a
HBV: hepatitis B virus; HCV: hepatitis C virus; ALC: alcohol consumption.  
b
AFP level was provided by Division of Gastroenterology, University of Michigan. 
c
MELD: Model for end-stage liver disease. 
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Huang et al. Scheme 1 
 
 
Figure Legend 
Scheme 1. An example of glycan structure nomenclature used in this report. The model 
glycan structure contains 4 HexNAc, 3 Mannose, 2 Galactose, 1 Fucose and 1 
Neuraminic acid residues. Hence, the nomenclature is [4-5-1-1]. Symbols: , 
GlcNAc; , mannose;  galactose; , fucose; , N-acetylneuraminic acid. 
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Huang et al. Figure 1 
 
Figure 1. Unsupervised PCA plot of the glycans that were quantitatively determined byC18-
LC-MS/MS analysis. The corresponding loading plot is shown in Figure S1. 
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Huang et al. Figure 2 
 
Figure 2. Base peak intensity chromatograms of LC-MS/MS analyses of permethylated 
glycans derived from sera collected from cirrhotic (a) and hepatocellular 
carcinoma (b) patients. The insets depict the MS of glycans depicting statistically 
significant differences between the two cohorts. Symbols: as in Scheme 1.  
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Figure 3. Box plots of normalized abundances of significant glycan structures based on the 
C18-LC-MS/MS analysis. Y-axis associated with glycans present at low abundances 
were 10x magnified. Asterisks indicate the level of statistical significance. Boxes 
depicted 25%  and 75% of the samples while the whiskers showed standard error. 
Symbols: as in Scheme 1. 
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Figure 4. Heat map of the C18-LC-MS/MS analysis of glycans that have illustrated 
significant differences between the two cohorts.  
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Huang et al. Figure 5 
 
Figure 5. Unsupervised PCA plot of the glycans that were quantitatively determined by 
PGC-LC-MS/MS analysis. The corresponding loading plot was shown in Figure S4.  
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Figure 6. Box plot of normalized abundances of the glycan structures that depicted 
significant different among the two cohorts upon PGC-LC-MS/MS analysis, Y-
axis associated with glycans present at low abundances were 10x magnified. The 
significant [5-6-1-3] refers to one of two isomers found with larger retention time, 
while for [5-6-2-3], to the left side is the first eluted isomer and on the right is the 
second isomer. Boxes depicted 25%  and 75% of the samples while the whiskers 
showed standard error. Asterisks indicate the level of statistical significance. 
Symbols: as in Scheme 1. 
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Huang et al. Figure 7 
Figure 7. EIC of biantennary monosialylated branch-fucosylated glycan linkage isomers 
derived from (a) cirrhotic and (b) hepatocellular carcinoma patients. (c) MS/MS 
interpretation of biantennary monosialylated branch-fucosylated glycan. Symbols: 
as in Scheme 1. 
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Figure 8. Heat map of the PGC LC-MS/MS analysis of glycans that have illustrated 
significance differences between the two cohorts, where [4-5-0-1,26] refers to the 
α-2,6 linked sialic acid and [4-5-1-1,26B] refers toα-2,6 linked sialic acid and a 
branch fucose.  
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